Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts


Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.


Bladder Immune Cells May Determine Response to Chemotherapy

Bladder Immune Cells May Determine Response to Chemotherapy

Scientist Woonyoung Choi, Ph.D., who led genomic studies that identified the basal and luminal molecular subtypes of bladder cancer, has discovered that the immune system plays a powerful role in how patients respond to chemotherapy.

“Differences in the numbers and characteristics of the immune cells – in particular, the T lymphocytes – that are present in bladder cancers strongly influence their sensitivity to neoadjuvant chemotherapy,” she says. With a $1.5 million grant from the Department of Defense, she is collaborating with a co-investigator in Texas to develop a new molecular subtyping test, and to perform mechanistic studies to determine whether T lymphocytes are required for bladder cancers to respond to chemotherapy.

back to top button